UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 3, 2018

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Ascendis Pharma A/S

File No. 1-36815 - CF#36168

Ascendis Pharma A/S submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on March 28, 2018.

Based on representations by Ascendis Pharma A/S that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 4.9 through December 31, 2025 Exhibit 4.10 through June 30, 2025

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary